Avoiding immunological rejection in regenerative medicine

Regenerative Medicine

Volumn 10, Issue 3, 2015, Pages 287-304

  Bolton, Eleanor M ^a   Bradley, John Andrew ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Belatacept; HLA matching; HLA typing; immunosuppression; mixed hematopoietic chimerism; stem cell banking; stem cell immunogenicity

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; ECULIZUMAB; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; EMBRYONIC STEM CELL; GENE THERAPY; GRAFT REJECTION; HISTOCOMPATIBILITY; HLA MATCHING; HLA TYPING; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REGULATORY T LYMPHOCYTE; REVIEW; RNA INTERFERENCE; STEM CELL TRANSPLANTATION; TISSUE TRANSPLANTATION; IMMUNOLOGY; PROCEDURES; STEM CELL;

GRAFT REJECTION; HUMANS; REGENERATIVE MEDICINE; STEM CELLS; TISSUE TRANSPLANTATION;

EID: 84929995123     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.15.11     Document Type: Review

References (179)

1. Okita K, Nagata N, Yamanaka S. Immunogenicity of induced pluripotent stem cells. Circ. Res. 109(7), 720-721 (2011).
2. Kaneko S, Yamanaka S. To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell 12(4), 385-386 (2013).
3. Fu X. The immunogenicity of cells derived from induced pluripotent stem cells. Cell Mol. Immunol. 11(1), 14-16 (2014).
4. Araki R, Uda M, Hoki Y et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494(7435), 100-104 (2013).
5. Guha P, Morgan JW, Mostoslavsky G, Rodrigues NP, Boyd AS. Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12(4), 407-412 (2013).
6. Morizane A, Doi D, Kikuchi T et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a nonhuman primate. Stem Cell Rep. 1(4), 283-292 (2013).
7. Sachamitr P, Hackett S, Fairchild PJ. Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy. Front. Immunol. 5, 176 (2014).
8. Scheiner ZS, Talib S, Feigal EG. The potential for immunogenicity of autologous induced pluripotent stem cellderived therapies. J. Biol. Chem. 289(8), 4571-4577 (2014).
9. Tang C, Weissman IL, Drukker M. Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives. Methods Mol. Biol. 1029, 17-31 (2013).
10. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 467(7313), 285-290 (2010).
11. Marchetto MC, Yeo GW, Kainohana O, Marsala M, Gage FH, Muotri AR. Transcriptional signature and memory retention of human-induced pluripotent stem cells. PLoS ONE 4(9), e7076 (2009).
12. Stelzer Y, Yanuka O, Benvenisty N. Global analysis of parental imprinting in human parthenogenetic induced pluripotent stem cells. Nat. Struct. Mol. Biol. 18(6), 735-741 (2011).
13. Zimmermann A, Preynat-Seauve O, Tiercy JM, Krause KH, Villard J. Haplotype-based banking of human pluripotent stem cells for transplantation: potential and limitations. Stem Cells Dev. 21(13), 2364-2373 (2012).
14. Bradley JA, Bolton EM, Pedersen RA. Stem cell medicine encounters the immune system. Nat. Rev. Immunol. 2(11), 859-871 (2002).
15. Drukker M, Katz G, Urbach A et al. Characterization of the expression of MHC proteins in human embryonic stem cells. Proc. Natl Acad. Sci. USA 99(15), 9864-9869 (2002).
16. Drukker M, Katchman H, Katz G et al. Human embryonic stem cells and their differentiated derivatives are less susceptible to immune rejection than adult cells. Stem Cells 24(2), 221-229 (2006).
17. Taylor CJ, Bolton EM, Pocock S, Sharples LD, Pedersen RA, Bradley JA. Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet 366(9502), 2019-2025 (2005).
18. Molne J, Bjorquist P, Andersson K et al. Blood group ABO antigen expression in human embryonic stem cells and in differentiated hepatocyte-And cardiomyocyte-like cells. Transplantation 86(10), 1407-1413 (2008).
19. Taylor CJ, Peacock S, Chaudhry AN, Bradley JA, Bolton EM. Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell 11(2), 147-152 (2012).
20. Taylor CJ, Bolton EM, Bradley JA. Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos. Trans. R Soc. Lond. B Biol. Sci. 366(1575), 2312-2322 (2011).
21. Sanchez Alvarado A, Yamanaka S. Rethinking differentiation: stem cells, regeneration, and plasticity. Cell 157(1), 110-119 (2014).
22. Nakatsuji N, Nakajima F, Tokunaga K. HLA-haplotype banking and iPS cells. Nat. Biotechnol. 26(7), 739-740 (2008).
23. Gourraud PA, Gilson L, Girard M, Peschanski M. The role of human leukocyte antigen matching in the development of multiethnic 'haplobank' of induced pluripotent stem cell lines. Stem Cells 30(2), 180-186 (2012).
24. Turner M, Leslie S, Martin NG et al. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell 13(4), 382-384 (2013).
25. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J. 19(7), 681-693 (2005).
26. Munn DH, Zhou M, Attwood JT et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281(5380), 1191-1193 (1998).
27. Aluvihare VR, Kallikourdis M, Betz AG. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5(3), 266-271 (2004).
28. Trowsdale J, Betz AG. Mother's little helpers: mechanisms of maternal-fetal tolerance. Nat. Immunol. 7(3), 241-246 (2006).
29. Taylor AW, Alard P, Yee DG, Streilein JW. Aqueous humor induces transforming growth factor-beta (TGF-beta)-producing regulatory T-cells. Curr. Eye Res. 16(9), 900-908 (1997).
30. Sharland A, Shastry S, Wang C et al. Kinetics of intragraft cytokine expression, cellular infiltration, and cell death in rejection of renal allografts compared with acceptance of liver allografts in a rat model: early activation and apoptosis is associated with liver graft acceptance. Transplantation 65(10), 1370-1377 (1998).
31. Suarez-Alvarez B, Rodriguez RM, Calvanese V et al. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells. PLoS ONE 5(4), e10192 (2010).
32. Land WG. Emerging role of innate immunity in organ transplantation: part II: potential of damage-Associated molecular patterns to generate immunostimulatory dendritic cells. Transplant. Rev. (Orlando) 26(2), 73-87 (2012).
33. Land WG. Emerging role of innate immunity in organ transplantation: part I: evolution of innate immunity and oxidative allograft injury. Transplant. Rev. (Orlando) 26(2), 60-72 (2012).
34. Land WG. Emerging role of innate immunity in organ transplantation: part III: the quest for transplant tolerance via prevention of oxidative allograft injury and its consequences. Transplant. Rev. (Orlando) 26(2), 88-102 (2012).
35. Peterson KM, Aly A, Lerman A, Lerman LO, Rodriguez-Porcel M. Improved survival of mesenchymal stromal cell after hypoxia preconditioning: role of oxidative stress. Life Sci. 88(1-2), 65-73 (2011).
36. Zhu W, Chen J, Cong X, Hu S, Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells 24(2), 416-425 (2006).
37. Sacks SH, Zhou W. The role of complement in the early immune response to transplantation. Nat. Rev. Immunol. 12(6), 431-442 (2012).
38. Kofidis T, deBruin JL, Tanaka M et al. They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. Eur. J. Cardiothorac. Surg. 28(3), 461-466 (2005).
39. Swijnenburg RJ, Tanaka M, Vogel H et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 112(9 Suppl.), I166-172 (2005).
40. Nussbaum J, Minami E, Laflamme MA et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 21(7), 1345-1357 (2007).
41. Swijnenburg RJ, Schrepfer S, Cao F et al. In vivo imaging of embryonic stem cells reveals patterns of survival and immune rejection following transplantation. Stem Cells Dev. 17(6), 1023-1029 (2008).
42. Wu DC, Boyd AS, Wood KJ. Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells 26(8), 1939-1950 (2008).
43. Robertson NJ, Brook FA, Gardner RL, Cobbold SP, Waldmann H, Fairchild PJ. Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proc. Natl Acad. Sci. USA 104(52), 20920-20925 (2007).
44. Frenzel LP, Abdullah Z, Kriegeskorte AK et al. Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. Stem Cells 27(2), 307-316 (2009).
45. Dressel R, Nolte J, Elsner L et al. Pluripotent stem cells are highly susceptible targets for syngeneic, allogeneic, and xenogeneic natural killer cells. FASEB J. 24(7), 2164-2177 (2010).
46. Preynat-Seauve O, de Rham C, Tirefort D, Ferrari-Lacraz S, Krause KH, Villard J. Neural progenitors derived from human embryonic stem cells are targeted by allogeneic T and natural killer cells. J. Cell Mol. Med. 13(9B), 3556-3569 (2009).
47. Ma M, Ding S, Lundqvist A et al. Major histocompatibility complex-I expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival. Stem Cells 28(9), 1465-1475 (2010).
48. Lindahl KF, Wilson DB. Histocompatibility antigen-Activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J. Exp. Med. 145(3), 508-522 (1977).
49. Lindahl KF, Wilson DB. Histocompatibility antigenactivated cytotoxic T lymphocytes. I. Estimates of the absolute frequency of killer cells generated in vitro. J. Exp. Med. 145(3), 500-507 (1977).
50. Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol. 29(1), 1-5 (1977).
51. Skinner MA, Marbrook J. An estimation of the frequency of precursor cells which generate cytotoxic lymphocytes. J. Exp. Med. 143(6), 1562-1567 (1976).
52. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr. Opin. Organ Transplant. 13(4), 438-444 (2008).
53. Bedford P, Garner K, Knight SC. MHC class II molecules transferred between allogeneic dendritic cells stimulate primary mixed leukocyte reactions. Int. Immunol. 11(11), 1739-1744 (1999).
54. Curry AJ, Pettigrew GJ, Negus MC et al. Dendritic cells internalise and represent conformationally intact soluble MHC class I alloantigen for generation of alloantibody. Eur. J. Immunol. 37(3), 696-705 (2007).
55. Sivaganesh S, Harper SJ, Conlon TM et al. Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells. J. Immunol. 190(11), 5829-5838 (2013).
56. Taylor AL, Negus SL, Negus M, Bolton EM, Bradley JA, Pettigrew GJ. Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation 83(7), 931-937 (2007).
57. Wood KJ, Goto R. Mechanisms of rejection: current perspectives. Transplantation 93(1), 1-10 (2012).
58. Okita K, Matsumura Y, Sato Y et al. A more efficient method to generate integration-free human iPS cells. Nat. Methods 8(5), 409-412 (2011).
59. Day E, Kearns PK, Taylor CJ, Bradley JA. Transplantation between monozygotic twins: how identical are they? Transplantation 98(5), 485-489 (2014).
60. Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O. Review article: use of induction therapy in liver transplantation. Transplant. Rev. (Orlando) 26(4), 246-260 (2012).
61. Morgan RD, O'Callaghan JM, Knight SR, Morris PJ. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-Analysis. Transplantation 93(12), 1179-1188 (2012).
62. Rush D. The impact of calcineurin inhibitors on graft survival. Transplant. Rev. (Orlando) 27(3), 93-95 (2013).
63. Salvadori M, Bertoni E Is It Time to Give Up with Calcineurin Inhibitors in Kidney Transplantation? World J. Transplant. 3(2), 7-25 (2013).
64. Russ GR. Optimising the use of mTOR inhibitors in renal transplantation. Transplant. Res. 2(Suppl. 1), S4 (2013).
65. Gurk-Turner C, Manitpisitkul W, Cooper M. A comprehensive review of everolimus clinical reports: a new mammalian target of rapamycin inhibitor. Transplantation 94(7), 659-668 (2012).
66. Davies NM, Grinyo J, Heading R, Maes B, Meier-Kriesche HU, Oellerich M. Gastrointestinal side effects of mycophenolic acid in renal transplant patients: a reappraisal. Nephrol. Dial. Transplant. 22(9), 2440-2448 (2007).
67. Jordan SC, Kahwaji J, Toyoda M, Vo A. B-cell immunotherapeutics: emerging roles in solid organ transplantation. Curr. Opin. Organ Transplant. 16(4), 416-424 (2011).
68. Wojciechowski D, Vincenti F. Belatacept in kidney transplantation. Curr. Opin. Organ Transplant. 17(6), 640-647 (2012).
69. Kotton CN. CMV: prevention, diagnosis and therapy. Am. J. Transplant. 13(Suppl. 3), 24-40; quiz 40 (2013).
70. Shoham S, Marr KA. Invasive fungal infections in solid organ transplant recipients. Future Microbiol. 7(5), 639-655 (2012).
71. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med. 348(17), 1681-1691 (2003).
72. Taylor AL, Marcus R, Bradley JA. Post-Transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit. Rev. Oncol. Hematol. 56(1), 155-167 (2005).
73. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am. J. Transplant. 13(Suppl. 3), 41-54; quiz 54 (2013).
74. Euvrard S, Morelon E, Rostaing L et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N. Engl. J. Med. 367(4), 329-339 (2012).
75. Pearl JI, Lee AS, Leveson-Gower DB et al. Short-Term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8(3), 309-317 (2011).
76. Swijnenburg RJ, Schrepfer S, Govaert JA et al. Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts. Proc. Natl Acad. Sci. USA 105(35), 12991-12996 (2008).
77. Grinnemo KH, Genead R, Kumagai-Braesch M et al. Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. Stem Cells 26(7), 1850-1857 (2008).
78. Ludwig B, Reichel A, Steffen A et al. Transplantation of human islets without immunosuppression. Proc. Natl Acad. Sci. USA 110(47), 19054-19058 (2013).
79. McCall M, Shapiro AM. Update on islet transplantation. Cold Spring Harb. Perspect. Med. 2(7), a007823 (2012).
80. Posselt AM, Szot GL, Frassetto LA et al. Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation 90(12), 1595-1601 (2010).
81. Nienhuis AW. Development of gene therapy for blood disorders: an update. Blood 122(9), 1556-1564 (2013).
82. Mitani K. Gene targeting in human-induced pluripotent stem cells with adenoviral vectors. Methods Mol. Biol. 1114, 163-167 (2014).
83. Gonzalez S, Castanotto D, Li H et al. Amplification of RNAitargeting HLA mRNAs. Mol. Ther. 11(5), 811-818 (2005).
84. Zhao J, Bolton EM, Ormiston ML, Bradley JA, Morrell NW, Lever AM. Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury. Transpl. Int. 25(2), 229-241 (2012).
85. Zhao J, Pettigrew GJ, Bolton EM et al. Lentivirus-mediated gene transfer of viral interleukin-10 delays but does not prevent cardiac allograft rejection. Gene Ther. 12(20), 1509-1516 (2005).
86. Raya A, Rodriguez-Piza I, Guenechea G et al. Diseasecorrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460(7251), 53-59 (2009).
87. Yusa K, Rashid ST, Strick-Marchand H et al. Targeted gene correction of alpha1-Antitrypsin deficiency in induced pluripotent stem cells. Nature 478(7369), 391-394 (2011).
88. Matrai J, Chuah MK, VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol. Ther. 18(3), 477-490 (2010).
89. Gaj T, Gersbach CA, Barbas CF, 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 31(7), 397-405 (2013).
90. Figueiredo C, Wedekind D, Muller T et al. MHC universal cells survive in an allogeneic environment after incompatible transplantation. Biomed. Res. Int. 2013, 796046 (2013).
91. Torikai H, Reik A, Soldner F et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122(8), 1341-1349 (2013).
92. Qian S, Fu F, Li Y et al. Impact of donor MHC class I or class II antigen deficiency on first-And second-set rejection of mouse heart or liver allografts. Immunology 88(1), 124-129 (1996).
93. Hacke K, Falahati R, Flebbe-Rehwaldt L, Kasahara N, Gaensler KM. Suppression of HLA expression by lentivirusmediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation. Immunol. Res. 44(1-3), 112-126 (2009).
94. Figueiredo C, Seltsam A, Blasczyk R. Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. J. Mol. Med. (Berl). 84(5), 425-437 (2006).
95. Beilke JN, Benjamin J, Lanier LL. The requirement for NKG2D in NK cell-mediated rejection of parental bone marrow grafts is determined by MHC class I expressed by the graft recipient. Blood 116(24), 5208-5216 (2010).
96. Rolstad B. The early days of NK cells: an example of how a phenomenon led to detection of a novel immune receptor system-lessons from a rat model. Front. Immunol. 5, 283 (2014).
97. Belanger S, Tu MM, Rahim MM et al. Impaired natural killer cell self-education and 'missing-self ' responses in Ly49-deficient mice. Blood 120(3), 592-602 (2012).
98. Matheux F, Villard J. Cellular and gene therapy for major histocompatibility complex class II deficiency. News Physiol. Sci. 19, 154-158 (2004).
99. Jaimes Y, Seltsam A, Eiz-Vesper B, Blasczyk R, Figueiredo C. Regulation of HLA class II expression prevents allogeneic T-cell responses. Tissue Antigens 77(1), 36-44 (2011).
100. Ke B, Buelow R, Shen XD et al. Heme oxygenase 1 gene transfer prevents CD95/Fas ligand-mediated apoptosis and improves liver allograft survival via carbon monoxide signaling pathway. Hum. Gene Ther. 13(10), 1189-1199 (2002).
101. Li J, Meinhardt A, Roehrich ME et al. Indoleamine 2, 3-dioxygenase gene transfer prolongs cardiac allograft survival. Am. J. Physiol. Heart Circ. Physiol. 293(6), H3415-H3423 (2007).
102. Olthoff KM, Judge TA, Gelman AE et al. Adenovirusmediated gene transfer into cold-preserved liver allografts: survival pattern and unresponsiveness following transduction with CTLA4Ig. Nat. Med. 4(2), 194-200 (1998).
103. Kim YH, Lim DG, Wee YM et al. Viral IL-10 gene transfer prolongs rat islet allograft survival. Cell Transplant. 17(6), 609-618 (2008).
104. Tomasoni S, Azzollini N, Casiraghi F, Capogrossi MC, Remuzzi G, Benigni A. CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J. Am. Soc. Nephrol. 11(4), 747-752 (2000).
105. Dudler J, Li J, Pagnotta M, Pascual M, von Segesser LK, Vassalli G. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 82(12), 1733-1737 (2006).
106. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp. Hematol. 4(5), 267-274 (1976).
107. Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284(5411), 143-147 (1999).
108. Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol. 24(4), 150-154 (2006).
109. Schallmoser K, Rohde E, Reinisch A et al. Rapid largescale expansion of functional mesenchymal stem cells from unmanipulated bone marrow without animal serum. Tissue Eng. Part C Methods. 14(3), 185-196 (2008).
110. Kuhbier JW, Weyand B, Radtke C, Vogt PM, Kasper C, Reimers K. Isolation, characterization, differentiation, and application of adipose-derived stem cells. Adv. Biochem. Eng. Biotechnol. 123, 55-105 (2010).
111. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol. Med. 16(5), 203-209 (2010).
112. Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-Analysis of clinical trials. PLoS ONE 7(10), e47559 (2012).
113. Lalu MM, McIntyre LL, Stewart DJ. Mesenchymal stromal cells: cautious optimism for their potential role in the treatment of acute lung injury. Crit. Care Med. 40(4), 1373-1375 (2012).
114. Krampera M, Glennie S, Dyson J et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101(9), 3722-3729 (2003).
115. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7), 2821-2827 (2005).
116. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57(1), 11-20 (2003).
117. Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (Lond). 2, 8 (2005).
118. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371(9624), 1579-1586 (2008).
119. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81(10), 1390-1397 (2006).
120. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and-9. Diabetes 58(8), 1797-1806 (2009).
121. Casiraghi F, Azzollini N, Cassis P et al. Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells. J. Immunol. 181(6), 3933-3946 (2008).
122. Inoue S, Popp FC, Koehl GE et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 81(11), 1589-1595 (2006).
123. Peng Y, Ke M, Xu L et al. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study. Transplantation 95(1), 161-168 (2013).
124. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrowderived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol. 251(2), 131-136 (2008).
125. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99(10), 3838-3843 (2002).
126. Corcione A, Benvenuto F, Ferretti E et al. Human mesenchymal stem cells modulate B-cell functions. Blood 107(1), 367-372 (2006).
127. Beyth S, Borovsky Z, Mevorach D et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105(5), 2214-2219 (2005).
128. Augello A, Tasso R, Negrini SM et al. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35(5), 1482-1490 (2005).
129. Krampera M, Cosmi L, Angeli R et al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24(2), 386-398 (2006).
130. Madec AM, Mallone R, Afonso G et al. Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52(7), 1391-1399 (2009).
131. Sato K, Ozaki K, Oh I et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109(1), 228-234 (2007).
132. Ramasamy R, Fazekasova H, Lam EW, Soeiro I, Lombardi G, Dazzi F. Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation 83(1), 71-76 (2007).
133. Probst HC, McCoy K, Okazaki T, Honjo T, van den Broek M. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6(3), 280-286 (2005).
134. Reis e Sousa C. Dendritic cells in a mature age. Nat. Rev. Immunol. 6(6), 476-483 (2006).
135. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-Tolerization of CD8+ T cells. Nat. Immunol. 2(11), 1010-1017 (2001).
136. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J. Immunol. 164(5), 2405-2411 (2000).
137. Hackstein H, Morelli AE, Larregina AT et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J. Immunol. 166(12), 7053-7062 (2001).
138. Woltman AM, de Fijter JW, Kamerling SW, Paul LC, Daha MR, van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur. J. Immunol. 30(7), 1807-1812 (2000).
139. Piemonti L, Monti P, Allavena P et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 162(11), 6473-6481 (1999).
140. Vieira PL, Kalinski P, Wierenga EA, Kapsenberg ML, de Jong EC. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J. Immunol. 161(10), 5245-5251 (1998).
141. Ramirez F, Fowell DJ, Puklavec M, Simmonds S, Mason D. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156(7), 2406-2412 (1996).
142. Chen T, Guo J, Yang M et al. Cyclosporin A impairs dendritic cell migration by regulating chemokine receptor expression and inhibiting cyclooxygenase-2 expression. Blood 103(2), 413-421 (2004).
143. Hoves S, Krause SW, Herfarth H et al. Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killerdendritic cells. Immunobiology 208(5), 463-475 (2004).
144. Feili-Hariri M, Falkner DH, Gambotto A et al. Dendritic cells transduced to express interleukin-4 prevent diabetes in nonobese diabetic mice with advanced insulitis. Hum. Gene Ther. 14(1), 13-23 (2003).
145. Salama AD, Womer KL, Sayegh MH. Clinical transplantation tolerance: many rivers to cross. J. Immunol. 178(9), 5419-5423 (2007).
146. Mirenda V, Berton I, Read J et al. Modified dendritic cells coexpressing self and allogeneic major histocompatability complex molecules: an efficient way to induce indirect pathway regulation. J. Am. Soc. Nephrol. 15(4), 987-997 (2004).
147. Wang Z, Shufesky WJ, Montecalvo A, Divito SJ, Larregina AT, Morelli AE. In situ targeting of dendritic cells with donor-derived apoptotic cells restrains indirect allorecognition and ameliorates allograft vasculopathy. PLoS ONE 4(3), e4940 (2009).
148. Sakaguchi S, Fukuma K, Kuribayashi K, Masuda T. Organspecific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-Tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J. Exp. Med. 161(1), 72-87 (1985).
149. Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J. Exp. Med. 177(3), 627-636 (1993).
150. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057-1061 (2003).
151. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
152. Yoshizaki A, Miyagaki T, Di Lillo DJ et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature 491(7423), 264-268 (2012).
153. Mauri C, Bosma A. Immune regulatory function of B cells. Annu. Rev. Immunol. 30, 221-241 (2012).
154. Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J. Exp. Med. 172(6), 1701-1708 (1990).
155. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8(2), 191-197 (2007).
156. Levings MK, Roncarolo MG. Phenotypic and functional differences between human CD4+CD25+ and type 1 regulatory T cells. Curr. Top Microbiol. Immunol. 293, 303-326 (2005).
157. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 37(1), 129-138 (2007).
158. Waldmann H, Chen TC, Graca L et al. Regulatory T cells in transplantation. Semin. Immunol. 18(2), 111-119 (2006).
159. Mizoguchi A, Bhan AK. A case for regulatory B cells. J. Immunol. 176(2), 705-710 (2006).
160. Ding Q, Yeung M, Camirand G et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J. Clin. Invest. 121(9), 3645-3656 (2011).
161. Maseda D, Candando KM, Smith SH et al. Peritoneal cavity regulatory B cells (B10 cells) modulate IFN-gamma+CD4+ T cell numbers during colitis development in mice. J. Immunol. 191(5), 2780-2795 (2013).
162. Kalampokis I, Yoshizaki A, Tedder TF. IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res. Ther. 15(Suppl.1), S1 (2013).
163. Geissler EK. The ONE study compares cell therapy products in organ transplantation: introduction to a review series on suppressive monocyte-derived cells. Transplant. Res. 1(1), 11 (2012).
164. Leventhal J, Abecassis M, Miller J et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLAmismatched combined kidney and hematopoietic stem cell transplantation. Sci. Transl. Med. 4(124), 124ra128 (2012).
165. Owen RD. Immunogenetic consequences of vascular anastomoses between Bovine twins. Science 102(2651), 400-401 (1945).
166. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 172(4379), 603-606 (1953).
167. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 307(5947), 168-170 (1984).
168. Tomita Y, Sachs DH, Khan A, Sykes M. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 61(3), 469-477 (1996).
169. Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat. Med. 6(4), 464-469 (2000).
170. Huang CA, Fuchimoto Y, Scheier-Dolberg R, Murphy MC, Neville DM, Jr., Sachs DH. Stable mixed chimerism and tolerance using a nonmyeloablative preparative regimen in a large-Animal model. J. Clin. Invest. 105(2), 173-181 (2000).
171. Kawai T, Cosimi AB, Spitzer TR et al. HLAmismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med. 358(4), 353-361 (2008).
172. Mathes DW, Chang J, Hwang B et al. Simultaneous transplantation of hematopoietic stem cells and a vascularized composite allograft leads to tolerance. Transplantation 98(2), 131-138 (2014).
173. Mathes DW, Hwang B, Graves SS et al. Tolerance to vascularized composite allografts in canine mixed hematopoietic chimeras. Transplantation 92(12), 1301-1308 (2011).
174. Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med. 358(4), 362-368 (2008).
175. Spitzer TR, McAfee SL, Dey BR et al. Nonmyeloablative haploidentical stem-cell transplantation using anti-CD2 monoclonal antibody (MEDI-507)-based conditioning for refractory hematologic malignancies. Transplantation 75(10), 1748-1751 (2003).
176. Takasato M, Er PX, Becroft M et al. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat. Cell Biol. 16(1), 118-126 (2014).
177. Lui KO, Zangi L, Silva EA et al. Driving vascular endothelial cell fate of human multipotent Isl1+ heart progenitors with VEGF modified mRNA. Cell Res. 23(10), 1172-1186 (2013).
178. Lippmann ES, Azarin SM, Kay JE et al. Derivation of bloodbrain barrier endothelial cells from human pluripotent stem cells. Nat. Biotechnol. 30(8), 783-791 (2012).
179. H-D Volk, Blackburn, Exploiting the regulatory T cell repertoire for the induction of tolerance in regenerative medicine. Regen. Med. 10(3), 305-315 (2015).